Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease

Infection

Volumn 44, Issue 1, 2016, Pages 65-76

  Sethi, S ^a,b   Anzueto, A ^c   Miravitlles, M ^d   Arvis, P ^e   Alder, J ^f   Haverstock, D ^f   Trajanovic, M ^g   Wilson, R ^h  

^a UNIVERSITY AT BUFFALO   (United States)

^b VA Medical Center   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e Europ NAD Mkt Development Manager   (France)

^f BAYER CORPORATION   (United States)

^g Bayer Inc   (Canada)

^h ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Bacteriological outcomes; Beta lactams; Exacerbation of chronic obstructive pulmonary disease; Fluoroquinolones; Risk factors; Systemic corticosteroids

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CORTICOSTEROID; MOXIFLOXACIN; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL SUPERINFECTION; BACTERIUM ISOLATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NONHUMAN; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL; REINFECTION; SPUTUM ANALYSIS; BACTERIUM; CLASSIFICATION; CLINICAL TRIAL; COMPLICATION; DOUBLE BLIND PROCEDURE; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PNEUMONIA, BACTERIAL; SPUTUM; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; BACTERIA; DOUBLE-BLIND METHOD; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM; TREATMENT OUTCOME;

EID: 84941712073     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-015-0833-3     Document Type: Article

References (35)

1. Spencer S, Jones PW, GLOBE Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. 2003;58:589–93.
2. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925–31.
3. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173:1114–21.
4. Mallia P, Footitt J, Sotero R, Jepson A, Contoli M, Trujillo-Torralbo MB, et al. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:1117–24.
5. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359:2355–65.
6. Llor C, Moragas A, Hernández S, Bayona C, Miravitlles M. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:716–23.
7. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, European Respiratory Society and European Society of Clinical Microbiology and Infectious Diseases, et al. Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect 2011;17:E1–E59.
8. Vestbo J, Hurd SS, Agusti A, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management and prevention of COPD. GOLD executive summary. Am J Respir Crit Care Med. 2013;187:345–65.
9. Wilson R, Anzueto A, Miravitlles M, Arvis P, Alder J, Haverstock D, et al. Moxifloxacin vs amoxicillin/clavulanic acid in outpatient AECOPD: MAESTRAL results. Eur Resp J. 2012;40:17–27.
10. Wilson R, Anzueto A, Miravitlles M, Arvis P, Faragó G, Haverstock D, et al. A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology. Int J Chron Obstruct Pulmon Dis. 2011;6:373–83.
11. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing MA07-A8, Wayne, CLSI, 2009. http://www.clsi.org/.
12. Miravitlles M, Espinosa C, Fernández-Laso E, Martos JA, Maldonado JA, Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest. 1999;116:40–6.
13. Miravitlles M. Epidemiology of chronic obstructive pulmonary disease exacerbations. Clin Pulm Med. 2002;9:191–7.
14. Weinreich UM, Korsgaard J. Bacterial colonisation of lower airways in health and chronic lung disease. Clin Respir J. 2008;2:116–22.
15. Garcha DS, Thurston SJ, Patel AR, Mackay AJ, Goldring JJ, Donaldson GC, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax. 2012;67:1075–80.
16. Perotin JM, Dury S, Renois F, Deslee G, Wolak A, Duval V, et al. Detection of multiple viral and bacterial infections in acute exacerbation of chronic obstructive pulmonary disease: a pilot prospective study. J Med Virol. 2013;85:866–73.
17. Cabrera-Rubio R, Garcia-Núñez M, Setó L, Antó JM, Moya A, Monsó E, et al. Microbiome diversity in the bronchial tracts of patients with chronic obstructive pulmonary disease. J Clin Microbiol. 2012;50:3562–8.
18. Sethi S. Molecular diagnosis of respiratory tract infection in acute exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis. 2011;52:S290–5.
19. Ulrich M, Berger J, Möller JG, Döring G. Moxifloxacin and ciprofloxacin protect human respiratory epithelial cells against Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae in vitro. Infection. 2005;33:50–4.
20. Kratzer C, Graninger W, Macfelda K, Buxbaum A, Georgopoulos A. Comparative activities of antibiotics against intracellular non-typeable Haemophilus influenzae. Wien Klin Wochenschr. 2007;119:297–302.
21. Murphy TF, Brauer AL, Schiffmacher AT, Sethi S. Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:266–72.
22. Miravitlles M, Kruesmann F, Haverstock D, Perroncel R, Choudhri SH, Arvis P. Sputum color and bacteria in chronic bronchitis exacerbations: a pooled analysis. Eur Respir J. 2012;39:1354–60.
23. Llor C, Bjerrum L, Munck A, Hansen MP, Córdoba GC, Strandberg EL, et al. Predictors for antibiotic prescribing in patients with exacerbations of COPD in general practice. Ther Adv Respir Dis. 2013;7:131–7.
24. Sethi S, Jones PW, Theron MS, Miravitlles M, Rubinstein E, Wedzicha JA, Wilson R, PULSE Study group. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res. 2010;11:10. doi:10.1186/1465-9921-11-10(Erratum in: Respir Res. 2010;11:88).
25. Berenson CS, Kruzel RL, Eberhardt E, Dolnick R, Minderman H, Wallace PK, et al. Impaired innate immune alveolar macrophage response and the predilection for COPD exacerbations. Thorax. 2014;69:811–8.
26. Berenson CS, Kruzel RL, Eberhardt E, Sethi S. Phagocytic dysfunction of human alveolar macrophages and severity of chronic obstructive pulmonary disease. J Infect Dis. 2013;208:2036–45.
27. Stolberg VR, McCubbrey AL, Freeman CM, Brown JP, Crudgington SW, Taitano SH, et al. Glucocorticoid-augmented efferocytosis inhibits pulmonary pneumococcal clearance in mice by reducing alveolar macrophage bactericidal function. J Immunol. 2015;195:174–84.
28. van de Garde MD, Martinez FO, Melgert BN, Hylkema MN, Jonkers RE, Hamann J. Chronic exposure to glucocorticoids shapes gene expression and modulates innate and adaptive activation pathways in macrophages with distinct changes in leukocyte attraction. J Immunol. 2014;192:1196–208.
29. Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186:48–55.
30. Gompertz S, O’Brien C, Bayley DL, Hill SL, Stockley RA. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J. 2001;17:1112–9.
31. Zhu J, Qiu YS, Majumdar S, Gamble E, Matin D, Turato G, et al. Exacerbations of bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care Med. 2001;164:109–16.
32. White AJ, Gompertz S, Bayley DL, Hill SL, O’Brien C, Unsal I, et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax. 2003;58:680–5.
33. Sethi S. New developments in the pathogenesis of acute exacerbations of chronic obstructive pulmonary disease. Curr Opin Infect Dis. 2004;17:113–9.
34. Adams SG, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest. 2000;117:1345–52.
35. Daniels JMA, Snijders D, de Graaff CS, Vlaspolder F, Jansen HM, Boersma WG. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181:150–7.